Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Reports on Map Pharmaceuticals

Sort by

Levadex Receives Complete Response Letter, What Does This Mean for the Stock? (MAPP, $16.44)

Sunday, April 8, 2012 · 1:22 pm

Read More

Levadex Has a Good Chance for Approval on its March 26th PDUFA Date (MAPP, $17.09)

Sunday, April 8, 2012 · 1:10 pm

Read More

Initiating Coverage of MAP Pharmaceuticals with A Buy Based On Potential for Levadex (MAPP, $13.35)

Thursday, December 15, 2011 · 10:53 am

Read More

There are 3 reports on file.

« Back to Company Reports Index